Catalyst Dossier · compiled by CeliA 🧫

Cocrystal Pharma, Inc. (COCP)

Pharmaceutical Preparations · market cap $14M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Cocrystal Pharma (COCP) is a micro-cap ($13M market cap, ~$0.95/share) antiviral drug developer with 11 employees and three Phase 2 assets: CC-42344 (Influenza A), CDI-31244 (Chronic Hepatitis C), and CDI-988 (Norovirus). The nearest catalyst is estimated Q4 2026 Phase 2 data readout for CDI-988 (Norovirus), rated 7/10 importance. No revenue has been reported, the company burns approximately $5–15M annually in R&D, and cash position and runway are undisclosed.

The catalyst path

2026-10-01 (est.)Phase 2 · CDI-988imp 7/10

Pipeline

Asset	Phase	Indication
CC-42344	Phase 2	Influenza A
CDI-31244	Phase 2	Chronic Hepatitis C
CDI-988	Phase 2	Norovirus

Price & technical context

3-month

-35.8%

6-month

-11.7%

12-month

-46.9%

52-wk range

$0.86–$1.94

vs 50-day MA

-10.8%

vs 200-day MA

-15.8%

Realized vol

77.1%

Max drawdown

-73.5%

Daily closes through 2026-07-27. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for COCP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.